Literature DB >> 17986219

Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.

Andreas Weiss1, Corinna Klein, Ben Woodman, Kirupa Sathasivam, Miriam Bibel, Etienne Régulier, Gillian P Bates, Paolo Paganetti.   

Abstract

A CAG-repeat gene expansion translated into a pathogenic polyglutamine stretch at the N-terminus of huntingtin triggers Huntington's Disease. Mutated huntingtin is predicted to adopt toxic properties mainly if aggregation-prone N-terminal fragments are released by proteolysis. Huntingtin-aggregates are indeed a major hallmark of this disorder and could represent useful markers of disease-onset or progression. We designed a simple method for qualitative and quantitative characterization of aggregates. For this, we analyzed samples from in vitro and in vivo Huntington's Disease models by agarose gel electrophoresis and showed that in the brain of transgenic mice huntingtin-aggregates became larger as a function of disease progression. This appears to be a property of cytoplasmic but not nuclear aggregates. In cell cultures, treatment with Congo Red inhibited aggregate growth but not total load. Finally, we showed that in primary striatal neurons and in brains of R6/2 and HdhQ150 mice, the presence of aggregates preceded initiation of any other functional deficits. This observation argues for a pathogenic role of huntingtin-aggregation in Huntington's Disease. Our results emphasize that thorough analysis of huntingtin metabolism and aggregation is now feasible, thus significantly improving the power of studies assessing therapies designed to lower huntingtin levels or to interfere with its aggregation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17986219     DOI: 10.1111/j.1471-4159.2007.05032.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  63 in total

1.  Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.

Authors:  Tyisha Hathorn; Abigail Snyder-Keller; Anne Messer
Journal:  Neurobiol Dis       Date:  2010-08-22       Impact factor: 5.996

Review 2.  Huntington's disease: progress toward effective disease-modifying treatments and a cure.

Authors:  Carl D Johnson; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

3.  Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool.

Authors:  Maya A Olshina; Lauren M Angley; Yasmin M Ramdzan; Jinwei Tang; Michael F Bailey; Andrew F Hill; Danny M Hatters
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

4.  Early autophagic response in a novel knock-in model of Huntington disease.

Authors:  Mary Y Heng; Duy K Duong; Roger L Albin; Sara J Tallaksen-Greene; Jesse M Hunter; Mathieu J Lesort; Alex Osmand; Henry L Paulson; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2010-07-08       Impact factor: 6.150

5.  Studying polyglutamine aggregation in Caenorhabditis elegans using an analytical ultracentrifuge equipped with fluorescence detection.

Authors:  Bashkim Kokona; Carrie A May; Nicole R Cunningham; Lynn Richmond; F Jay Garcia; Julia C Durante; Kathleen M Ulrich; Christine M Roberts; Christopher D Link; Walter F Stafford; Thomas M Laue; Robert Fairman
Journal:  Protein Sci       Date:  2015-12-21       Impact factor: 6.725

Review 6.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

7.  p62 plays a protective role in the autophagic degradation of polyglutamine protein oligomers in polyglutamine disease model flies.

Authors:  Yuji Saitoh; Nobuhiro Fujikake; Yuma Okamoto; H Akiko Popiel; Yusuke Hatanaka; Morio Ueyama; Mari Suzuki; Sébastien Gaumer; Miho Murata; Keiji Wada; Yoshitaka Nagai
Journal:  J Biol Chem       Date:  2014-12-05       Impact factor: 5.157

8.  Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.

Authors:  Eva L Morozko; Joseph Ochaba; Sarah J Hernandez; Alice Lau; Isabella Sanchez; Iliana Orellana; Lexi Kopan; Joshua Crapser; Janet H Duong; Julia Overman; Silvia Yeung; Joan S Steffan; Jack Reidling; Leslie M Thompson
Journal:  J Huntingtons Dis       Date:  2018

9.  Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Authors:  Erik Kvam; Brent L Nannenga; Min S Wang; Zongjian Jia; Michael R Sierks; Anne Messer
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease.

Authors:  Kirupa Sathasivam; Amin Lane; Justin Legleiter; Alice Warley; Ben Woodman; Steve Finkbeiner; Paolo Paganetti; Paul J Muchowski; Stuart Wilson; Gillian P Bates
Journal:  Hum Mol Genet       Date:  2010-01-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.